Lung Disease-Focused Insmed 'Must-Own' Name For Investors Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.
Russell Rebalance: 3 Stocks Ready to Move Higher The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them?
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.
